Compare SLGL & ANIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLGL | ANIK |
|---|---|---|
| Founded | 1997 | 1983 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.8M | 134.8M |
| IPO Year | 2018 | 1993 |
| Metric | SLGL | ANIK |
|---|---|---|
| Price | $49.36 | $9.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $50.00 | $16.00 |
| AVG Volume (30 Days) | 19.6K | ★ 153.9K |
| Earning Date | 11-20-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $18,970,000.00 | ★ $112,806,000.00 |
| Revenue This Year | $121.82 | N/A |
| Revenue Next Year | N/A | $4.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 62.04 | 30.55 |
| 52 Week Low | $4.02 | $7.87 |
| 52 Week High | $54.54 | $18.37 |
| Indicator | SLGL | ANIK |
|---|---|---|
| Relative Strength Index (RSI) | 72.77 | 55.14 |
| Support Level | $40.10 | $9.31 |
| Resistance Level | $44.99 | $9.85 |
| Average True Range (ATR) | 3.02 | 0.20 |
| MACD | 0.60 | 0.04 |
| Stochastic Oscillator | 91.68 | 79.63 |
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.